Type 2 & other diabetes

Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists

Diabetes Obes MetabPublished Retrospective cohort study

Authors' conclusion

No increased risk of peri- and postoperative complications in GLP1-RA users undergoing surgery with general endotracheal anaesthesia was identified.

Study context

Population
US adults with diabetes on oral hypoglycaemic agents undergoing general endotracheal anaesthesia during nine common surgical procedures; nationally representative electronic health dataset, 1 January 2015–1 April 202316.5% on GLP1-RA
Participants
13,361 adults
Exposure
GLP-1 RA users vs non-users
Outcome
Six peri- and postoperative complications: composite of postoperative decelerated gastric emptying (antiemetic use, ileus within 7 days, gastroparesis diagnosis, gastric emptying study); aspiration or pneumonitis; severe respiratory failure; postoperative hypoglycaemia; inpatient mortality; 30-day mortality
Methodological detailsobservational, high-dimensionality propensity score-matched, sensitivity analysis in diabetes and obesity
  • Observational
  • High-dimensionality propensity score-matched
  • Sensitivity analysis in diabetes and obesity

Main finding

As reported in the abstract

Peri- and postoperative complications
  • Lower risk of decelerated gastric emptying and antiemetic use with GLP1-RA users vs non-users
  • Risk of ileus within 7 days, aspiration/pneumonitis, hypoglycaemia and 30-day mortality not different
  • High-dimensionality propensity score-matched cohort

Observational data: associations, not effects.

Further findings

Sensitivity analysis: patients with diabetes and obesity

Similar findings in patients with diabetes and obesity

Original publication

Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists. Diabetes Obes Metab. Published 14 May 2024. doi:10.1111/dom.15636

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.